The goal of this observational study is to evaluate the quality of life, drug safety and therapy compliance of schizophrenia or bipolar affective disorder patients during the treatment with quetiapine monotherapy or in combination with another antipsychotic/antipsychotics. The main outcome measures are:
* quality of life using the World Health Organization Quality of Life questionnaire (WHOQOL) * safety through the monitoring of the incidence of possible adverse drug events by the researcher, with the assessment of the association between the administration of the drug and the occurrence of an adverse reaction * therapy adherence using the Medication Adherence Rating Scale (MARS).
The subjects will be divided into two groups:
1. Newly diagnosed patients with a diagnosis of schizophrenia or bipolar affective disorder whose individual therapeutic approach, based on the clinical assessment of the research physician, includes one of the following therapies:
1. monotherapy with the drug quetiapine 2. combined antipsychotic therapy with quetiapine and aripiprazole 3. combined antipsychotic therapy with quetiapine and haloperidol 2. Patients with a diagnosis of schizophrenia or bipolar affective disorder who are on therapy with one of the antipsychotics (aripiprazole or haloperidol), and who, based on the clinical assessment of the investigator, require adjunctive quetiapine therapy. This group will include two subgroups of patients:
1. combined antipsychotic therapy with quetiapine and aripiprazole 2. combined antipsychotic therapy with quetiapine and haloperidol Recruitment of subjects will be carried out by physicians/researchers based on the patient's history and diagnosis. The diagnosis of schizophrenia or bipolar affective disorder will be based on the standard diagnostic criteria in medical practice (validated measurement scales in psychiatry - Young's Mania Scale, Beck Depression Scale and PANNS Schizophrenia Scale).
Patients will have four visits to physician/researcher:
1. First visit - baseline at which patient will be included in the study 2. Second visit - 4 months after the baseline 3. Third visit - 8 months after the baseline 4. Fourth visit - 12 months after the baseline
Persons over 18 years of age and under 65 years of age.
Schizophrenia or bipolar affective disorder established by the usual diagnostic criteria applied in a psychiatric clinic or hospital ward/unit within the clinic or outpatient.
Patients who are treated as outpatients, inpatients or have been discharged from the clinic/hospital with a recommendation for quetiapine monotherapy or combination therapy of quetiapine with aripiprazole or haloperidol. Recommended by a specialist psychiatrist/neuropsychiatrist in clinical and hospital centers and through specialist-consultant outpatient clinics in Bosnia and Herzegovina.
Persons younger than 18 years and older than 65 years
Hypersensitivity to the components of the drug
Positive history of angioneurotic edema
Pregnancy
Schizophrenia or bipolar affective disorder patients of both sexes aged 18 to 65 years.
Cohort
Prospective
Quetiapine (drug)
DrugMonotherapy with the drug quetiapine
quetiapine + aripiprazole
DrugCombined antipsychotic therapy with quetiapine and aripiprazole
quetiapine + haloperidol
DrugCombined antipsychotic therapy with quetiapine and haloperidol
Measurement of quality of life using the World Health Organization Quality of Life questionnaire (WHOQOL)
Evaluation of the quality of life of patients during treatment for schizophrenia or bipolar affective disorder using monotherapy with the drug quetiapine or combination therapy with the drug quetiapine and another antipsychotic (aripiprazole or haloperidol).
Safety assessment through incidence of possible adverse drug events and evaluation of the association between the administration of the drug and the occurrence of an adverse reaction
Safety through the monitoring of the incidence of possible adverse drug events by the researcher, with the assessment of the association between the administration of the drug and the occurrence of an adverse reaction
Therapy adherence using the Medication Adherence Rating Scale (MARS)
Click on the lead sponsor to view all of their trials.
